Clincosm LogoSign in Get a demo

Carcinoma, Hepatocellular

Showing NaN - NaN of 39
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)

Recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +62 more
Feb 1, 2023

Carcinoma, Hepatocellular Trial in Worldwide (drug, biological, procedure)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Tucson, Arizona
  • +206 more
Jan 31, 2023

Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer Trial in Worldwide (RO7119929, Tocilizumab)

Completed
  • Carcinoma, Hepatocellular
  • +3 more
  • Duarte, California
  • +9 more
Jan 27, 2023

Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Tepotinib 300 mg
  • +4 more
  • Beijing, Beijing, China
  • +42 more
Aug 22, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +138 more
Aug 22, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)

Active, not recruiting
Has Results
  • Carcinoma, Hepatocellular
  • Phoenix, Arizona
  • +118 more
Jun 14, 2022

Carcinoma, Hepatocellular Trial in Taiwan (PI-88)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Kaohsiung, Taiwan
  • +5 more
Jun 21, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))

Completed
  • Carcinoma, Hepatocellular
  • Refametinib (BAY86-9766)
  • Sorafenib (BAY43-9006)
  • Louisville, Kentucky
  • +78 more
Apr 6, 2021

Carcinoma, Hepatocellular Trial in Taiwan (Atezolizumab, Bevacizumab)

Recruiting
  • Carcinoma, Hepatocellular
  • Kaohsiung, Taiwan
  • +7 more
Mar 26, 2021

Carcinoma, Hepatocellular Trial in Worldwide (Regorafenib (Stivarga, BAY73-4506), Placebo)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Regorafenib (Stivarga, BAY73-4506)
  • Placebo
  • Los Angeles, California
  • +146 more
Aug 11, 2020

Carcinoma, Hepatocellular Trial in Worldwide (Placebo, GC33)

Completed
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +56 more
Apr 1, 2020

Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (JNJ-42756493 (erdafitinib))

Completed
  • Carcinoma, Hepatocellular
  • JNJ-42756493 (erdafitinib)
  • Changchun, China
  • +9 more
Feb 17, 2020

Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Sorafenib (Nexavar, BAY43-9006)
  • +2 more
  • San Francisco, California
  • +126 more
May 16, 2019

Carcinoma, Hepatocellular Trial in Tainan, Taipei, Taoyuan City (Ramucirumab, FOLFOX4)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Tainan, Taiwan
  • +2 more
May 3, 2018

Carcinoma, Hepatocellular Trial in Taipei (Lipotecan® (TLC388))

Terminated
  • Carcinoma, Hepatocellular
  • Lipotecan® (TLC388)
  • Taipei, Taiwan
  • +1 more
Aug 20, 2018

Carcinoma, Hepatocellular Trial in Busan, Taipei (OBP-301)

Unknown status
  • Carcinoma, Hepatocellular
  • OBP-301
  • Busan, Korea, Republic of
  • +1 more
Aug 16, 2018

Carcinoma, Hepatocellular Trial in Worldwide (Nexavar (Sorafenib, BAY43-9006), Placebo)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Nexavar (Sorafenib, BAY43-9006)
  • Placebo
  • Birmingham, Alabama
  • +198 more
Jul 11, 2018

Carcinoma, Hepatocellular Trial in San Francisco, Hong Kong, Taipei (pazopanib)

Completed
  • Carcinoma, Hepatocellular
  • San Francisco, California
  • +2 more
Nov 13, 2017

Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Placebo)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Sorafenib (Nexavar, BAY43-9006)
  • Placebo
  • La Jolla, California
  • +106 more
Jul 18, 2017

Carcinoma, Hepatocellular Trial in Hong Kong, Taiwan, Thailand (Foretinib)

Completed
  • Carcinoma, Hepatocellular
  • Hong Kong, Hong Kong
  • +6 more
Jul 14, 2017

HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related

Unknown status
  • Carcinoma, Hepatocellular
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jan 11, 2017

    Carcinoma, Hepatocellular Trial in Worldwide (Onartuzumab, Sorafenib)

    Completed
    • Carcinoma, Hepatocellular
    • Sarasota, Florida
    • +9 more
    Nov 1, 2016

    Carcinoma, Hepatocellular Trial in Tainan, Taipei, Taoyuan (Vandetanib, Best Supportive Care)

    Completed
    Has Results
    • Carcinoma, Hepatocellular
    • Tainan, Taiwan
    • +2 more
    Aug 29, 2016

    Carcinoma, Hepatocellular Trial in Korea, Republic of, Taiwan (Sorafenib, BIBF 1120)

    Completed
    Has Results
    • Carcinoma, Hepatocellular
    • Seoul, Korea, Republic of
    • +15 more
    Feb 9, 2016

    Carcinoma, Hepatocellular Trial in Taipei (Operation)

    Completed
    • Carcinoma, Hepatocellular
    • Operation
    • Taipei, Taiwan
      Far Eastern Memorial Hospital
    Feb 4, 2016